Development
Sanofi's BsAb lunsekimig hits endpoints for asthma, CRSwNP, falls short in dermatitis
Sanofi (EURONEXT: SAN; NASDAQ: SNY) reported that lunsekimig, its bispecific Nanobody targeting both TSLP and IL-13, met primary and key secondary endpoints...
Praxis reports early positive data for antisense drug elsunersen in SCN2A genetic epilepsy
Praxis Precision Medicines (Nasdaq: PRAX) reported positive Phase I/II data from the EMBRAVE Part A trial of elsunersen in pediatric SCN2A developmental...
Tenvie Therapeutics initiates Phase I trial of NLRP3 inhibitor in obesity
Tenvie Therapeutics, a Brisbane, California-based biotech, announced the dosing of the first subject in a Phase I/Ib clinical study of TNV262, a small...
Alar's ketamine therapy meets safety goals in treatment-resistant depression Phase I
Alar Pharmaceuticals, a Taiwan-based clinical-stage company listed on the TPEx exchange, reported Phase I results for ALA-3000, a subcutaneous...
Ideaya's KAT6/7 inhibitor enters Phase I for breast, prostate, colorectal, and lung cancer
IDEAYA Biosciences announced on April 6 that the first patient has been dosed in a Phase I dose-escalation trial of IDE574, an oral small molecule designed...
Amgen's subcutaneous Tepezza meets primary endpoint in Phase III thyroid eye disease trial
Amgen (NASDAQ: AMGN) reported that a Phase III trial of subcutaneous teprotumumab-trbw (Tepezza) delivered via an on-body injector met its primary endpoint...
Immunome's 177Lu-IM-3050 enters Phase I trial targeting fibroblast activation protein-alpha
Immunome, Inc. has registered a first-in-human Phase 1 clinical trial for 177Lu-IM-3050, a lutetium-177-labeled radioligand targeting fibroblast activation...
Sunho Biologics' long-acting FGF21 fusion protein enters Phase I in China for hypertriglyceridemia
Sunho Biologics has registered a first-in-human Phase 1 clinical trial for ISH0688, a recombinant human IgG1 Fc-FGF21 fusion protein targeting...
Ferring pulls development of LHCGR-targeted fertility drug
Ferring Pharmaceuticals has terminated the Phase I Celestial-1 trial (NCT06466486), a study evaluating FE 999302 (choriogonadotropin beta, a recombinant...
Data committee gives nod for Vedanta's VE303 to advance in Phase III for C. difficile infection prevention
Vedanta Biosciences reported that an independent data monitoring committee has recommended the Phase III RESTORATiVE303 trial of VE303 continue without...
Alphamab's anbenitamab meets primary endpoint in Phase III HER2-positive breast cancer trial
Alphamab Oncology (HKEX: 9966) announced on March 31 that anbenitamab (KN026), a bispecific anti-HER2 antibody, met its primary endpoint in the Phase III...
Immedica's lurbinectedin-atezolizumab combination gets CHMP nod for ES-SCLC maintenance
Lurbinectedin (Zepzelca) combined with atezolizumab has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products...
University of Colorado Anschutz Gates Institute's CD64 CAR T-cell therapy gets IND for AML
The University of Colorado Anschutz Gates Institute announced FDA clearance of an Investigational New Drug application for a CD64-directed CAR T-cell...
Revolution Medicines kickstarts Phase III daraxonrasib trial targeting first-line RAS-driven pancreatic cancer
Revolution Medicines has begun enrolling patients in RASolute 303 (NCT07491445), a Phase 3 trial testing daraxonrasib (RMC-6236) as a first-line treatment...
AstraZeneca's durvalumab, tremelimumab combo hits PFS goals in liver cancer
AstraZeneca (LSE/STO/NYSE: AZN) reported that the combination of durvalumab (Imfinzi), tremelimumab (Imjudo), lenvatinib, and transarterial...
The AllSci Brief
Systematic R&D and deal news. Daily.